What is the share price of Alembic Ltd (ALEMBICLTD) today?
The share price of ALEMBICLTD as on 13th March 2025 is ₹92.59. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alembic Ltd (ALEMBICLTD) share?
The past returns of Alembic Ltd (ALEMBICLTD) share are- Past 1 week: -5.25%
- Past 1 month: -11.53%
- Past 3 months: -37.43%
- Past 6 months: -36.87%
- Past 1 year: 10.62%
- Past 3 years: 10.16%
- Past 5 years: 119.93%
What are the peers or stocks similar to Alembic Ltd (ALEMBICLTD)?
The peers or stocks similar to Alembic Ltd (ALEMBICLTD) include:What is the dividend yield % of Alembic Ltd (ALEMBICLTD) share?
The current dividend yield of Alembic Ltd (ALEMBICLTD) is 2.60.What is the market cap of Alembic Ltd (ALEMBICLTD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Ltd (ALEMBICLTD) is ₹2370.64 Cr as of 13th March 2025.What is the 52 week high and low of Alembic Ltd (ALEMBICLTD) share?
The 52-week high of Alembic Ltd (ALEMBICLTD) is ₹169 and the 52-week low is ₹78.10.What is the PE and PB ratio of Alembic Ltd (ALEMBICLTD) stock?
The P/E (price-to-earnings) ratio of Alembic Ltd (ALEMBICLTD) is 8.83. The P/B (price-to-book) ratio is 1.08.Which sector does Alembic Ltd (ALEMBICLTD) belong to?
Alembic Ltd (ALEMBICLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alembic Ltd (ALEMBICLTD) shares?
You can directly buy Alembic Ltd (ALEMBICLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alembic Ltd
ALEMBICLTDAlembic Ltd
ALEMBICLTD
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,370 cr, stock is ranked 969
High RiskStock is 3.33x as volatile as Nifty
92.591.18% (-1.11)
92.591.18% (-1.11)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 7.54 | 1.08 | 2.60% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.84 | 5.96 | 0.56% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Limited is engaged in the business of pharmaceuticals, real estate and power assets. The Company's segments include API and Real Estate.
Peers
Compare with peersSUNPHARMA
PE Ratio
42.06
1Y Return
7.21%
Buy Reco %
88.24
CIPLA
PE Ratio
28.56
1Y Return
2.32%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
62.26
1Y Return
13.59%
Buy Reco %
68.00
DRREDDY
PE Ratio
16.50
1Y Return
11.99%
Buy Reco %
45.16
MANKIND
PE Ratio
47.34
1Y Return
3.73%
Buy Reco %
80.00
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 162.76 | 178.13 | 162.32 | 153.26 | 167.33 | 83.79 | 167.40 | 191.50 | 212.26 | 284.62 | ||||||||||
Raw Materials | 37.64 | 50.97 | 39.86 | 45.21 | 24.59 | 11.77 | 8.53 | 6.92 | 8.62 | 120.12 | ||||||||||
| Power & Fuel Cost | 13.26 | 5.46 | 1.11 | 2.34 | 0.91 | 0.42 | 0.15 | 2.02 | 1.18 | |||||||||||
| Employee Cost | 27.01 | 28.64 | 19.64 | 20.52 | 20.79 | 22.60 | 21.47 | 24.04 | 23.03 | |||||||||||
| Selling & Administrative Expenses | 7.62 | 7.38 | 7.13 | 7.26 | 9.17 | 7.56 | 9.82 | 10.81 | 14.04 | |||||||||||
| Operating & Other expenses | 45.64 | 53.80 | 46.45 | 30.41 | 15.19 | 20.10 | 24.33 | 53.73 | 53.76 | |||||||||||
EBITDA | 31.59 | 31.88 | 48.13 | 47.52 | 96.68 | 21.34 | 103.10 | 93.98 | 111.63 | 164.50 | ||||||||||
| Depreciation/Amortization | 6.14 | 5.09 | 3.78 | 2.63 | 3.23 | 3.94 | 4.86 | 6.72 | 7.84 | 9.35 | ||||||||||
| PBIT | 25.45 | 26.79 | 44.35 | 44.89 | 93.45 | 17.40 | 98.24 | 87.26 | 103.79 | 155.15 | ||||||||||
| Interest & Other Items | 0.12 | 0.16 | 0.17 | 0.22 | 0.29 | 0.36 | 0.39 | 0.47 | 1.11 | 2.33 | ||||||||||
| PBT | 25.33 | 26.63 | 44.18 | 44.67 | 93.16 | 17.04 | 97.85 | 86.79 | 102.68 | 152.82 | ||||||||||
| Taxes & Other Items | -209.18 | -118.75 | -118.81 | -168.43 | -235.95 | -325.80 | -124.20 | -103.85 | -165.93 | -161.56 | ||||||||||
| Net Income | 234.51 | 145.38 | 162.99 | 213.10 | 329.11 | 342.84 | 222.05 | 190.64 | 268.61 | 314.38 | ||||||||||
| EPS | 7.15 | 4.43 | 4.97 | 6.62 | 11.50 | 13.35 | 8.65 | 7.42 | 10.46 | 12.24 | ||||||||||
| DPS | 0.12 | 0.16 | 0.16 | 0.16 | 0.60 | 0.20 | 1.80 | 2.20 | 2.40 | 2.40 | ||||||||||
| Payout ratio | 0.02 | 0.04 | 0.03 | 0.02 | 0.05 | 0.01 | 0.21 | 0.30 | 0.23 | 0.20 |
Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alembic Ltd | 8.83 | 1.08 | 2.60% |
| Sun Pharmaceutical Industries Ltd | 42.06 | 6.00 | 0.80% |
| Cipla Ltd | 28.56 | 4.39 | 0.89% |
| Torrent Pharmaceuticals Ltd | 62.26 | 15.04 | 0.92% |
Price Comparison
Compare ALEMBICLTD with any stock or ETFCompare ALEMBICLTD with any stock or ETF
ALEMBICLTD
Shareholdings
Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
Mutual Funds
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 2.60%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹26.00 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 5, 2024
Final
Final | Div/Share: ₹2.40
Dividend/Share
₹2.40
Ex DateEx Date
Aug 5, 2024
Cash Dividend
Ex DateEx DateAug 3, 2023
Final
Final | Div/Share: ₹2.20
Dividend/Share
₹2.20
Ex DateEx Date
Aug 3, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Final
Final | Div/Share: ₹1.80
Dividend/Share
₹1.80
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateJul 29, 2021
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Jul 29, 2021
Cash Dividend
Ex DateEx DateJul 29, 2020
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Jul 29, 2020
News & Opinions
Articles & Videos
Spotlight
Alembic Q3 PAT soars to Rs 26 cr
Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago. Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review. The company's revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review. On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24. Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business. Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales57.9239.32 47 OPM %45.5829.68 - PBDT30.0813.53 122 PBT27.3910.87 152 NP65.3961.40 6 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Alembic to hold board meeting
Alembic will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 33.46% in the September 2024 quarter
Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales52.9132.28 64 OPM %37.0131.44 - PBDT84.5157.89 46 PBT81.8356.03 46 NP121.0290.68 33 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Alembic announces board meeting date
Alembic will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 25.78% in the June 2024 quarter
Net profit of Alembic rose 25.78% to Rs 55.82 crore in the quarter ended June 2024 as against Rs 44.38 crore during the previous quarter ended June 2023. Sales rose 37.84% to Rs 50.78 crore in the quarter ended June 2024 as against Rs 36.84 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales50.7836.84 38 OPM %40.1729.53 - PBDT21.8713.38 63 PBT19.3711.55 68 NP55.8244.38 26 Powered by Capital Market - Live
7 months agoCapital Market - Live
Alembic’s shares dip amidst US market product recall
1 year agoThe Hindu Businessline
Housing & Urban Development Corporation Ltd leads gainers in ‘A’ group
2 years agoBusiness Standard
Alembic Ltd leads gainers in ‘A’ group
2 years agoBusiness Standard
This multibagger stock sets record date for 90% dividend
2 years agoLivemint
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.73%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.07% to 0.06%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 4.74%, vs industry avg of 15.28%